p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: Relation to prognosis

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 155-160

  Pappot, Helle ^a,b   Francis, Dorthe ^c   Brünner, Nils ^a   Grøndahl Hansen, Jan ^a   Østerlind, Kell ^d  

^a FINSEN LABORATORY   (Denmark)

^b University of Copenhagen   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d HILLERØD HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030033010     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lane, D. P. p53, guardian of the genome. Nature (Lond.), 358: 15-16. 1992.
2. Lane, D. P. Cancer. A death in the life of p53. Nature (Lond.), 362: 786-787, 1993.
3. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
4. Hollstein M , Sidransky, D., Vogelstein, B , and Harris, C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991.
5. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335: 675-679, 1990.
6. Chaba, I., Takahashi, T., Nau, M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H , Reissman, P. T., Slamon, D. J., Carmack Holmes, E., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610, 1990.
7. Bodner, S. M., Minna, J. D., Jensen, S. M., D'Amico, D., Carbone, D., Mitsudomi, T., Fedorko, J., Buchhagen, D. L., Nau, M. M., Gazdar, A. F , and Linnoila, R. I. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7: 743-749, 1992.
8. Miller, C. W., Simon, K., Aslo, A., Kok, K., Yokota, J., Buys, C. H., Terada, M , and Koeffler, H. P. p53 mutations in human lung tumors. Cancer Res., 52: 1695-1698. 1992.
9. Lane, D. P. The regulation of p53 function: Steiner award lecture. Int. J. Cancer, 57: 623-621, 1994.
10. Carbone, D. P., and Minna, J. D. The molecular genetics of lung cancer. Adv. Intern. Med. 37: 153-171, 1992.
11. Kalemkerian, G. P. Biology of lung cancer. Curr. Opin. Oncol., 6: 147-155, 1994.
12. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., and Shimokata, K. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993.
13. Mitsudomi, T., Oyama, T., Kusano, T., Osaki T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst., 55:2018-2023, 1993.
14. McLaren, R., Kuzu, I., Dunnill, M., Harris, A., Lane, D., and Gatter, K. C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66: 735-738. 1992.
15. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
16. M̊rkve, O., Halvorsen, O. J., Skjaerven, R., Stangeland, L., Gulsvik, A., and Laerum, O. D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res., 13: 571-578, 1993.
17. Passlick, B., Izbicki, J. R., and Riethmüller, G. p53 in non-small-cell lung cancer. J. Natl. Cancer Inst., 86: 801-802, 1994.
18. Volm, M., and Mattern, J. Immunohistochemical detection of p53 in non-small-cell lung cancer. J. Natl. Cancer Inst., 86: 1240, 1994.
19. Harpole, D. H., Herndon, J. E., Wolfe, G. W., Iglehart, J. D., and Marks, J. R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res., 55: 51-56, 1995.
20. Dane, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S . and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44: 139-266, 1985.
21. Blasi, F., Vassalli, J. D., and Danø, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801-804, 1987.
22. Liotta, L. A., and Steeg, P. S. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
23. Pöllänen, J., Stephens, R. W., and Vaheri, A. Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res., 57: 273-328, 1991.
24. Pedersen, H., Francis, D , Grøndahl-Hansen, J., Østerlind, K., Hansen, H. H., Danø, K., and Brunner, N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
25. Pedersen, H., Brunner, N., Francis, D., Østerlind, K., Rønne, E., Hansen, H. H., Danø, K., and Grøndahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
26. Danø, K., Behrendt, N., Brunner, N., Ploug, M., and Pyke, C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 8: 189-203, 1994.
27. Mountain, C., Lukeman, J., Hammar, S., Chamberlain, D., Coulson, W., Page, D., Victor, T., Weiland, L., and the Lung Cancer Study Group Pathology Committee. Lung cancer classification: the relationship of disease extent and cell type to survival in a clinical trials population. J. Surg. Oncol., 35: 147-156, 1987.
28. WHO. Histological Typing of Lung Tumours, Ed. 2. Geneva: WHO, 1981.
29. Cox, D. R. Regression models and life tahles (with discussion). J. R. Statist. Soc., 187: 187-220, 1972.
30. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbone, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res., 52: 4168-4174, 1992.
31. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., and Ueda, R. p53 mutations in non small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52: 734-736, 1992.
32. Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., and Sehya, T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52: 4799-4804, 1992.
33. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bousk, N. Control of angiogenesis in fibroblasts by p53 regulation of throrabospondin-1. Science (Wash. DC). 265: 1582-1584, 1994.
34. Kolberg, R. Angiogenic inhibitor loss may key to post-surgery metastasis. J. NIH Res., 6: 31-33, 1994.